Scarica l'app Stockscreener
60.35
2.65%
1.56
Dopo l'orario di chiusura:
60.34
-0.010
-0.02%
Precedente Chiudi:
$58.79
Aprire:
$59.64
Volume 24 ore:
1.28M
Relative Volume:
0.63
Capitalizzazione di mercato:
$11.66B
Reddito:
$3.29B
Utile/perdita netta:
$268.74M
Rapporto P/E:
44.04
EPS:
1.3704
Flusso di cassa netto:
$759.12M
1 W Prestazione:
+5.47%
1M Prestazione:
+6.31%
6M Prestazione:
-1.57%
1 anno Prestazione:
+5.12%
Intervallo 1D:
$58.63
$60.54
Intervallo di 1 settimana:
$57.25
$60.54
Portata 52W:
$49.26
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.35 | 11.36B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Ripresa | Morgan Stanley | Overweight |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-20 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BMRN Maintained by RBC Capital -- Price Target Lowered to $62 - GuruFocus
BioMarin Pharmaceutical updates its rare disease pipeline. Focus on long-term growth and innovation - AD HOC NEWS
RBC Capital Lowers BioMarin Pharmaceutical Price Target to $62 From $66, Maintains Sector Perform Rating - marketscreener.com
Trading Systems Reacting to (BMRN) Volatility - Stock Traders Daily
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating - ChartMill
BMRNBiomarin Pharmaceutical Inc Options - Finviz
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
The top 12 companies hiring in biopharma now - BioSpace
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Value-Defensive Index - marketscreener.com
BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued? - Sahm
What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma - Kavout | AI
BioMarin Pharmaceutical, Friday analyst angle, shares in focus - Ad-hoc-news.de
BioMarin (BMRN) up 0.2% since last earnings report: Can it continue? - MSN
BMRN Stock Price, Quote & Chart - ChartMill
Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh - TradingView
BioMarin Pharmaceutical Inc. Actuals & Estimates (NASDAQ:BMRN) - TradingView
Price to sales forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
BMRN Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
Price to book forward of BioMarin Pharmaceutical Inc. – GETTEX:BM8 - TradingView
Price to book forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
Price to earnings forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing - Stock Traders Daily
BioMarin Pharmaceutical Inc (BMRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment - Insider Monkey
10 Most Promising Stocks with Highest Upside Potential - Insider Monkey
BioMarin stock maintained at Neutral by H.C. Wainwright on trial data - Investing.com UK
Stifel reiterates Hold on BioMarin stock, keeps $68 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Hold on BioMarin stock, keeps $68 price target - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unpacking A 60% Upside Potential - DirectorsTalk Interviews
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk - Sahm
BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Chart - ChartMill
BioMarin Pharmaceutical Inc (BMRN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Institutional Confidence - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioMarin Pharmaceutical Inc - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioMarin presents three-year VOXZOGO data for hypochondroplasia By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. Presents New Three-Year VOXZOGO Data in Hypochondroplasia and BMN 333 Early Results At ENDO 2026 - marketscreener.com
BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments - marketscreener.com
BioMarin presents three-year VOXZOGO data for hypochondroplasia - Investing.com
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - PR Newswire
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring a Potential 57% Upside Opportunity - DirectorsTalk Interviews
(BMRN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):